Description

Product Description

Insulin Peglispro is a long-acting basal insulin analog, engineered to provide sustained glycemic control for preclinical research applications. Chemically modified through pegylation, the peptide demonstrates reduced clearance, prolonged half-life, and flat pharmacodynamic profile, distinguishing it from conventional human insulin and other basal analogs.

The primary mechanism of Insulin Peglispro involves insulin receptor activation in peripheral tissues such as skeletal muscle and adipose tissue. Upon receptor engagement, it stimulates glucose uptake, glycogen synthesis, and lipid metabolism regulation, while suppressing hepatic glucose output. This dual action allows laboratories to study basal glucose homeostasis, insulin signaling, and metabolic regulation under controlled experimental conditions.

Preclinical studies using rodent and non-human primate models have shown that Insulin Peglispro provides stable basal insulin coverage, minimizing glucose fluctuations and reducing the risk of hypoglycemia compared to conventional insulin preparations. Its flat activity profile enables continuous basal insulin exposure, facilitating investigations into glycemic control dynamics, insulin resistance, and beta-cell function.

In translational research, Insulin Peglispro is particularly valuable for studying type 1 and type 2 diabetes, obesity-related insulin resistance, and pharmacokinetics of long-acting insulin analogs. Its pegylation not only prolongs systemic exposure but also reduces the frequency of experimental dosing, enhancing reproducibility and laboratory efficiency.

The GMP-grade production ensures high purity, consistent batch quality, and structural integrity, crucial for laboratory research and preclinical studies. The lyophilized peptide is stable under standard storage conditions, allowing long-term experiments in cellular, tissue, and whole-animal models.

Additionally, Insulin Peglispro supports mechanistic research into insulin receptor signaling, glucose transporter dynamics, hepatic glucose production, and the interaction of basal insulin with other hormonal modulators such as glucagon, GLP-1, and amylin. This versatility makes it an indispensable tool for laboratories investigating glycemic regulation, diabetes pharmacology, and metabolic disease mechanisms.

?? Disclaimer: For laboratory research use only. Not for human or veterinary use.

Product Specifications

Insulin Peglispro’s specifications ensure consistent peptide quality, reproducible pharmacodynamic effects, and suitability for extensive preclinical investigations in metabolic research.

Mechanism of Action & Research Applications

Insulin Peglispro exerts its biological activity by binding to the insulin receptor (IR), a tyrosine kinase receptor expressed in peripheral tissues. Upon binding, the receptor undergoes autophosphorylation, initiating a cascade of intracellular signaling events that regulate glucose uptake, glycogen synthesis, and lipid metabolism. Pegylation of Insulin Peglispro extends its half-life and provides a flat pharmacodynamic profile, reducing peak-to-trough variability in blood glucose.

Mechanism Overview:

1. Insulin Receptor Activation
   Peglispro binds IR with high affinity, stimulating GLUT4 translocation to the cell membrane and enhancing glucose uptake into skeletal muscle and adipose tissue.

2. Hepatic Glucose Suppression
   Basal insulin activity inhibits hepatic gluconeogenesis and glycogenolysis, promoting stable basal glucose levels.

3. Prolonged Activity via Pegylation
   The PEG moiety reduces renal clearance and proteolytic degradation, allowing sustained insulin action and minimal glycemic fluctuations.

4. Signaling Pathways
   Activation of PI3K/AKT and MAPK pathways facilitates cellular metabolism, growth, and survival, enabling mechanistic studies of insulin action.

Research Applications:

• Diabetes Models
  Study basal insulin requirements, glucose homeostasis, and insulin resistance in type 1 and type 2 diabetes models.

• Glycemic Control Studies
  Evaluate pharmacokinetics, dose-response, and comparative efficacy of long-acting insulin analogs.

• Insulin Signaling Research
  Explore receptor activation, GLUT4 trafficking, and downstream metabolic pathways in vitro and in vivo.

• Metabolic Syndrome Investigations
  Examine the interaction of basal insulin with obesity, hepatic steatosis, and lipid metabolism.

• Combination Therapy Models
  Assess synergistic effects with GLP-1 analogs, amylin analogs, or other metabolic agents.

• Mechanistic Studies
  Investigate insulin receptor desensitization, feedback loops with glucagon, and counterregulatory hormonal responses.

• Translational Research
  Inform development of long-acting insulin therapies with improved pharmacodynamic profiles and reduced hypoglycemia risk.

Insulin Peglispro’s flat, prolonged activity profile and GMP-grade reproducibility make it a versatile tool for comprehensive studies in glycemic regulation, diabetes pharmacology, and endocrine research.

Side Effects (For Reference in Research Models)

Experimental observations in preclinical models include:

• Hypoglycemia Risk
  Dose-dependent plasma glucose reduction may occur; careful monitoring is required.

• Hepatic and Renal Responses
  Changes in glycogen content or enzyme activity may be observed in high-dose studies.

• Cardiovascular Effects
  Mild transient effects on heart rate or blood pressure reported in animal models.

• Weight and Metabolic Effects
  Chronic studies may show alterations in body weight or lipid metabolism due to prolonged insulin activity.

• Injection Site Reactions
  Local irritation may occur in subcutaneous administration models.

• Pharmacokinetic Considerations
  Stability is maintained in lyophilized form; repeated freeze-thaw cycles should be avoided.

• Experimental Model Observations
  Effects may vary depending on species, dosage, diet, and experimental design.

?? These observations are strictly for laboratory research reference. Insulin Peglispro is not intended for human or veterinary use. Researchers should adhere to standard laboratory safety protocols.

Disclaimer

For laboratory research use only. Not for human or veterinary use.

Keywords

• Insulin Peglispro

• Insulin Peglispro CAS 1200440-65-8

• BIL insulin analog

• Basal insulin research peptide

• Glycemic control research peptide

• GMP supplier Insulin Peglispro

• Diabetes research peptide

• Long-acting insulin analog

• Laboratory glucose regulation peptide

• Preclinical metabolic research peptide